CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients

ABSTRACT Molecular biomarkers may facilitate the distinction between aggressive and clinically insignificant prostate cancer (PCa), thereby potentially aiding individualized treatment. We analyzed cysteine dioxygenase 1 (CDO1) promoter methylation and mRNA expression in order to evaluate its potential as prognostic biomarker. CDO1 methylation and mRNA expression were determined in cell lines and formalin-fixed paraffin-embedded prostatectomy specimens from a first cohort of 300 PCa patients using methylation-specific qPCR and qRT-PCR. Univariate and multivariate Cox proportional hazards and Kaplan-Meier analyses were performed to evaluate biochemical recurrence (BCR)-free survival. Results were confirmed in an independent second cohort comprising 498 PCa cases. Methylation and mRNA expression data from the second cohort were generated by The Cancer Genome Atlas (TCGA) Research Network by means of Infinium HumanMethylation450 BeadChip and RNASeq. CDO1 was hypermethylated in PCa compared to normal adjacent tissues and benign prostatic hyperplasia (P < 0.001) and was associated with reduced gene expression (ρ = −0.91, P = 0.005). Using two different methodologies for methylation quantification, high CDO1 methylation as continuous variable was associated with BCR in univariate analysis (first cohort: HR = 1.02, P = 0.002, 95% CI [1.01–1.03]; second cohort: HR = 1.02, P = 0.032, 95% CI [1.00–1.03]) but failed to reach statistical significance in multivariate analysis. CDO1 promoter methylation is involved in gene regulation and is a potential prognostic biomarker for BCR-free survival in PCa patients following radical prostatectomy. Further studies are needed to validate CDO1 methylation assays and to evaluate the clinical utility of CDO1 methylation for the management of PCa.

[1]  Kun-Ling Tsai,et al.  Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[3]  X. Ni,et al.  ROS-mediated DNA methylation pattern alterations in carcinogenesis. , 2015, Current drug targets.

[4]  S. Chai,et al.  Probes of the Catalytic Site of Cysteine Dioxygenase* , 2006, Journal of Biological Chemistry.

[5]  D. Sidransky,et al.  Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer , 2016, PloS one.

[6]  G. Kristiansen,et al.  Nucleic acid-based tissue biomarkers of urologic malignancies , 2014, Critical reviews in clinical laboratory sciences.

[7]  T. Daniels,et al.  Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75 , 2009, Molecular Cancer.

[8]  M. Maroney,et al.  Cysteine dioxygenase: structure and mechanism. , 2007, Chemical communications.

[9]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[10]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[11]  G. Kristiansen,et al.  Performance Evaluation of Kits for Bisulfite-Conversion of DNA from Tissues, Cell Lines, FFPE Tissues, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine , 2014, PloS one.

[12]  J. Foekens,et al.  CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients , 2010, BMC Cancer.

[13]  K. D. Sørensen,et al.  Prognostic DNA Methylation Markers for Prostate Cancer , 2014, International journal of molecular sciences.

[14]  Jana Jeschke,et al.  MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data , 2015, BMC Genomics.

[15]  G. Kristiansen,et al.  Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia , 2014, Virchows Archiv.

[16]  Juna Lee,et al.  Cysteine Dioxygenase 1 Is a Tumor Suppressor Gene Silenced by Promoter Methylation in Multiple Human Cancers , 2012, PloS one.

[17]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[18]  J. Ross,et al.  Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. , 2008, Oncology reports.

[19]  Y. Furuta,et al.  Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells , 2008, Oncogene.

[20]  Ye Tian,et al.  C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study. , 2015, Experimental cell research.

[21]  E. Park,et al.  Taurine: new implications for an old amino acid. , 2003, FEMS microbiology letters.

[22]  P. A. van den Brandt,et al.  Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome , 2015, Clinical Cancer Research.

[23]  P. Clark,et al.  Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression , 2011, PloS one.

[24]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[25]  M. Rubin,et al.  Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. , 2012, Cancer discovery.

[26]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[27]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[28]  J. Dominy,et al.  Overexpression of cysteine dioxygenase reduces intracellular cysteine and glutathione pools in HepG2/C3A cells. , 2007, American journal of physiology. Endocrinology and metabolism.

[29]  M. Pawlita,et al.  High‐throughput SNP‐based authentication of human cell lines , 2013, International journal of cancer.

[30]  Yingjin Yuan,et al.  Amplification loop cascade for increasing caspase activity induced by docetaxel , 2005, Journal of cellular biochemistry.

[31]  O. Griffith,et al.  Biologic and pharmacologic regulation of mammalian glutathione synthesis. , 1999, Free radical biology & medicine.

[32]  Erik Schrumpf,et al.  Novel target genes and a valid biomarker panel identified for cholangiocarcinoma , 2012, Epigenetics.

[33]  G. Kristiansen,et al.  Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer , 2015, Oncotarget.

[34]  S. Freedland,et al.  Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. , 2010, Journal of Urology.

[35]  M. Shimizu,et al.  Functional characterization and regulation of the taurine transporter and cysteine dioxygenase in human hepatoblastoma HepG2 cells. , 2003, The Biochemical journal.

[36]  G. Kristiansen.  Diagnostic and prognostic molecular biomarkers for prostate cancer , 2012, Histopathology.

[37]  J. Herman,et al.  Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines , 2013, Clinical Cancer Research.

[38]  P. Schumacker,et al.  Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? , 2014, Nature Reviews Cancer.

[39]  J. Dominy,et al.  Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels , 2009, Amino Acids.

[40]  G. Kristiansen,et al.  The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer , 2015, Clinical Cancer Research.

[41]  D. Sidransky,et al.  Detection of Methylated CDO1 in Plasma of Colorectal Cancer; A PCR Study , 2014, PloS one.

[42]  G. Kristiansen,et al.  DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. , 2009, The Journal of urology.

[43]  G. Kristiansen,et al.  Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer—what has gone wrong? A blueprint for the way forward in biomarker studies , 2014, British Journal of Cancer.

[44]  K. D. Sørensen,et al.  DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. D. Sørensen,et al.  Hypermethylation of the GABRE∼miR-452∼miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy , 2014, Clinical Cancer Research.